Martin Johansson, CEO of Glactone Pharma AB, to present at Biotech Showcase™.

“Investors and biopharmaceutical executives from around the world gather in San Francisco during this week and therefore it is important for us to be there and to further strengthen Glactone Pharma’s position as the leader in discovery and development of direct small-molecule STAT3 inhibitors,” said Martin Johansson.

Glactone Pharma is actively profiling novel small-molecule inhibitors of STAT3 for the treatment of prostate cancer and for the use in immuno-oncology areas where a STAT3 inhibitor has great potential to address large unmet medical needs and help patients.

Jan Törnell, Chairman of the Board, and Martin Johansson, CEO, will represent Glactone Pharma at the Biotech Showcase™ which is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential partners in one place during the course of one of the industry’s largest annual healthcare investor conferences.

When and where:
Wednesday, January 13, 2016, at 4:45 PM
Track: E – Davidson (4th Floor)
Parc 55 San Francisco – Union Square

About Biotech Showcase™ 2016, visit

Glactone Pharma
Glactone Pharma is a biopharmaceutical company within PULS, a unique Swedish development company in life sciences, and is based on ground-breaking science from the University of Lund in Sweden. Glactone Pharma has developed a pipeline of novel potential drugs that target the STAT3 transcription factor for the use in immuno-oncology and for the treatment of castration resistant prostate cancer (CRPC). STAT3 is directly involved in tumor mediated immune suppression and resistance to androgen inhibition therapy making it an ideal target in combination treatments. To read more visit

For more information and contact
Jan Törnell, Chairman of the Board, Glactone Pharma, +46 (0)70-676 00 08 or
Martin Johansson, CEO, Glactone Pharma, +1 705 768 0603 or